Literature DB >> 17505301

The priming effect of C5a on monocytes is predominantly mediated by the p38 MAPK pathway.

Valérie Schaeffer1, Joseph Cuschieri, Iris Garcia, Megan Knoll, Jens Billgren, Sandra Jelacic, Eileen Bulger, Ronald Maier.   

Abstract

The dysregulation of the inflammatory response after trauma leads to significant morbidity and mortality. Monocytes and macrophages play a central role in the orchestration of the inflammatory response after injury. Serum interleukin-6 (IL-6) concentration correlates with poor outcomes after injury. Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine that plays a crucial role in the pathogenesis of multiple organ dysfunction syndrome. Furthermore, in the presence of C5a, monocytes and macrophages have potentiated responses, but the mechanisms underlying this response remain largely unknown. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers and pretreated with C5a (100 ng/mL) for 1 h before adding lipopolysaccharide (LPS) (10 ng/mL) for up to 20 h. Inhibitors for the mitogen-activated protein kinases (MAPKs) were added 1 h before adding C5a. C5a primes monocytes for LPS-induced IL-6 and TNF-alpha production. Treatment of PBMCs with C5a leads to a rapid activation of the 3 MAPK pathways. SP600125 (inhibitor of c-Jun NH2-terminal kinase MAPK) and PD98059 (inhibitor of extracellular signal-regulated kinase MAPK) did not affect the C5a priming of the LPS-induced IL-6 and TNF-alpha production, whereas SB203580, a specific inhibitor of p38 MAPK, did suppress the C5a priming effect. These results demonstrate that C5a primes adherent PBMCs and modulates LPS-induced IL-6 and TNF-alpha production. Results from extracellular signal-regulated kinase and c-Jun NH2-terminal kinase MAPK blockade suggest that these signaling pathways have minimal or no role in reprogramming LPS-mediated IL-6 and TNF-alpha production. On the contrary, in PBMCs, C5a activates the p38 cascade, and this pathway plays a major role in the C5a enhancement of LPS-induced IL-6 and TNF-alpha production.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505301      PMCID: PMC6014696          DOI: 10.1097/SHK.0b013e31802fa0bd

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  49 in total

1.  Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression.

Authors:  Niels C Riedemann; Thomas A Neff; Ren-Feng Guo; Kurt D Bernacki; Ines J Laudes; J Vidya Sarma; John D Lambris; Peter A Ward
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

Review 2.  Injury, sepsis, and the regulation of Toll-like receptor responses.

Authors:  Thomas J Murphy; Hugh M Paterson; John A Mannick; James A Lederer
Journal:  J Leukoc Biol       Date:  2003-10-13       Impact factor: 4.962

3.  G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK.

Authors:  Andrea la Sala; Massimo Gadina; Brian L Kelsall
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

4.  Blockade of p38 map kinase inhibits complement-induced acute lung injury in a murine model.

Authors:  Steven P Nash; Rita M Heuertz
Journal:  Int Immunopharmacol       Date:  2005-06-22       Impact factor: 4.932

5.  Linking the "two-hit" response following injury to enhanced TLR4 reactivity.

Authors:  Thomas J Murphy; Hugh M Paterson; Sara Kriynovich; Yan Zang; Evelyn A Kurt-Jones; John A Mannick; James A Lederer
Journal:  J Leukoc Biol       Date:  2004-10-20       Impact factor: 4.962

6.  C5a differentially stimulates the ERK1/2 and p38 MAPK phosphorylation through independent signaling pathways to induced chemotactic migration in RAW264.7 macrophages.

Authors:  Wen-Fei Chiou; Hwei-Ru Tsai; Li-Ming Yang; Wei-Jern Tsai
Journal:  Int Immunopharmacol       Date:  2004-10       Impact factor: 4.932

7.  Mitogen-activated protein kinases in the intensive care unit: prognostic potential.

Authors:  Matthew R Rosengart; Avery B Nathens; Saman Arbabi; Margaret J Neff; Iris Garcia; Thomas R Martin; Ronald V Maier
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

8.  Anti-interleukin-6 antibody treatment improves survival during gut-derived sepsis in a time-dependent manner by enhancing host defense.

Authors:  R Gennari; J W Alexander
Journal:  Crit Care Med       Date:  1995-12       Impact factor: 7.598

9.  C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and Bad-mediated signalling pathway.

Authors:  M C Perianayagam; V S Balakrishnan; B J G Pereira; B L Jaber
Journal:  Eur J Clin Invest       Date:  2004-01       Impact factor: 4.686

10.  Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.

Authors:  Judith Branger; Bernt van den Blink; Sebastiaan Weijer; Jeffrey Madwed; Carina L Bos; Abhya Gupta; Chan-Loi Yong; Stephen H Polmar; Dariusz P Olszyna; C Erik Hack; Sander J H van Deventer; Maikel P Peppelenbosch; Tom van der Poll
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

View more
  13 in total

1.  Early complementopathy after multiple injuries in humans.

Authors:  Anne-Maud Burk; Myriam Martin; Michael A Flierl; Daniel Rittirsch; Matthias Helm; Lorenz Lampl; Uwe Bruckner; Gregory L Stahl; Anna M Blom; Mario Perl; Florian Gebhard; Markus Huber-Lang
Journal:  Shock       Date:  2012-04       Impact factor: 3.454

2.  Role of the mTOR pathway in LPS-activated monocytes: influence of hypertonic saline.

Authors:  Valérie Schaeffer; Saman Arbabi; Iris A Garcia; Megan L Knoll; Joseph Cuschieri; Eileen M Bulger; Ronald V Maier
Journal:  J Surg Res       Date:  2010-06-09       Impact factor: 2.192

3.  Complement mediates a primed inflammatory response after traumatic lung injury.

Authors:  J Jason Hoth; Jonathan D Wells; Sarah E Jones; Barbara K Yoza; Charles E McCall
Journal:  J Trauma Acute Care Surg       Date:  2014-03       Impact factor: 3.313

Review 4.  The potential of p38 MAPK inhibitors to modulate periodontal infections.

Authors:  Keith L Kirkwood; Carlos Rossa
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

5.  Complement c5a generation by staphylococcal biofilms.

Authors:  Ashley E Satorius; Jacob Szafranski; Derek Pyne; Mahesh Ganesan; Michael J Solomon; Duane W Newton; David M Bortz; John G Younger
Journal:  Shock       Date:  2013-04       Impact factor: 3.454

6.  p38 mitogen-activated protein kinase inhibition decreases TNFalpha secretion and protects against left ventricular remodeling in rats with myocardial ischemia.

Authors:  Huiqiu Yin; Jidong Zhang; Haiqing Lin; Rong Wang; Yun Qiao; Bo Wang; Fenye Liu
Journal:  Inflammation       Date:  2007-10-18       Impact factor: 4.092

7.  p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation.

Authors:  Jian Hao; Li-Qiang Meng; Peng-Cheng Xu; Min Chen; Ming-Hui Zhao
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

8.  C5 deficiency and C5a or C5aR blockade protects against cerebral malaria.

Authors:  Samir N Patel; Joanne Berghout; Fiona E Lovegrove; Kodjo Ayi; Andrea Conroy; Lena Serghides; Gundula Min-oo; D Channe Gowda; J Vidya Sarma; Daniel Rittirsch; Peter A Ward; W Conrad Liles; Philippe Gros; Kevin C Kain
Journal:  J Exp Med       Date:  2008-04-21       Impact factor: 14.307

9.  C5a Induces the Synthesis of IL-6 and TNF-α in Rat Glomerular Mesangial Cells through MAPK Signaling Pathways.

Authors:  Mingde Ji; Yanlai Lu; Chenhui Zhao; Wenxing Gao; Fengxia He; Jing Zhang; Dan Zhao; Wen Qiu; Yingwei Wang
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

10.  Alternative Complement Pathway Activation Provokes a Hypercoagulable State with Diminished Fibrinolysis.

Authors:  Jason M Samuels; Julia R Coleman; Ernest E Moore; Matt Bartley; Navin Vigneshwar; Mitchell Cohen; Christopher C Silliman; Angela Sauaia; Anirban Banerjee
Journal:  Shock       Date:  2020-05       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.